...
首页> 外文期刊>Journal of Neurochemistry: Offical Journal of the International Society for Neurochemistry >Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.
【24h】

Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain.

机译:血浆纤溶酶原激活物的活性受到抑制,而神经丝氨酸蛋白酶抑制剂在阿尔茨海默氏病大脑中被上调。

获取原文
获取原文并翻译 | 示例

摘要

Amyloid-beta plaques are a pathological hallmark of Alzheimer's disease. Several proteases are known to cleave/remove amyloid-beta, including plasmin, the product of tissue plasminogen activator cleavage of the pro-enzyme plasminogen. Although plasmin levels are lower in Alzheimer brain, there has been little analysis of the plasminogen activator/plasmin system in the brains of Alzheimer patients. In this study, zymography, immunocapture, and ELISAs were utilized to show that tissue plasminogen activator activity in frontal cortex tissue of Alzheimer patients is dramatically reduced compared with age-matched controls, while tissue plasminogen activator and plasminogen protein levels are unchanged; suggesting that plasminogen activator activity is inhibited in the Alzheimer brain. Analysis of endogenous plasminogen activator inhibitors shows that while plasminogen activator inhibitor-1 and protease nexin-1 levels are unchanged, the neuroserpin levels are significantly elevated in brains of Alzheimer patients. Furthermore, elevated amounts of tissue plasminogen activator-neuroserpin complexes are seen in the Alzheimer brain, and immunohistochemical studies demonstrate that both tissue plasminogen activator and neuroserpin are associated with amyloid-beta plaques in Alzheimer brain tissue. Thus, neuroserpin inhibition of tissue plasminogen activator activity leads to reduced plasmin and may be responsible for reduced clearance of amyloid-beta in the Alzheimer disease brain. Furthermore, decreased tissue plasminogen activator activity in the Alzheimer brain may directly influence synaptic activity and impair cognitive function.
机译:β淀粉样蛋白斑块是阿尔茨海默氏病的病理标志。已知几种蛋白酶可裂解/去除淀粉样β蛋白,包括纤溶酶,其是酶原纤溶酶原的组织纤溶酶原激活物裂解的产物。尽管阿尔茨海默氏症患者脑中的纤溶酶水平较低,但对阿尔茨海默氏症患者大脑中的纤溶酶原激活剂/纤溶酶系统的分析很少。在这项研究中,酶谱,免疫捕获和酶联免疫吸附试验显示,与年龄相匹配的对照组相比,阿尔茨海默氏病患者额叶皮层组织中的纤溶酶原激活物活性显着降低,而组织纤溶酶原激活物和纤溶酶原蛋白水平未改变;提示纤溶酶原激活物的活性在阿尔茨海默氏病大脑中受到抑制。内源性纤溶酶原激活物抑制剂的分析表明,虽然纤溶酶原激活物抑制剂1和蛋白酶nexin-1水平没有变化,但神经丝氨酸蛋白酶抑制剂水平在阿尔茨海默病患者的大脑中显着升高。此外,在阿尔茨海默氏病脑中发现组织纤溶酶原激活物-neuroserpin复合物数量增加,免疫组织化学研究表明,组织纤溶酶原激活物和神经丝氨酸蛋白酶抑制剂均与阿尔茨海默病脑组织中的淀粉样蛋白斑块相关。因此,神经丝氨酸蛋白酶抑制剂对组织纤溶酶原激活物活性的抑制导致纤溶酶降低,并可能导致阿尔茨海默病脑中淀粉样β清除率降低。此外,阿尔茨海默氏病脑组织纤溶酶原激活物活性的降低可能直接影响突触活性并损害认知功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号